Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Cree B.; Bennett J.; Kim H.; Weinshenker B.; Pittock S.; Wingerchuk D.; Fujihara K.; Paul F.; Cutter G.; Marignier R.; Green A.; Aktas O.; Hartung H.; Lublin F.; Drappa J.; Barron G.; Madani Soraya; Ratchford J.; She D.; Cimbora D.; Katz E.

doi:10.1016/s0140-6736(19)31817-3

← Today's brief

Study

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Cree B. et al. · Lancet · Tuesday, January 1, 2019

Read original

n 230Funding Not reported

Source

Cree B. et al.. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. Tuesday, January 1, 2019.
doi:10.1016/s0140-6736(19)31817-3

Generated, then checked claim-by-claim against the source · how this brief was built →

Physician-designed methodology · Amr Saad, MD MBA

Sign in to rate and bookmark articles

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.